Abstract
At the request of Sage Publishing and the Managing Editor, the following article has been retracted:
Ma H, Dean DC, Wei R, et al. Cyclin-dependent kinase 7 (CDK7) is an emerging prognostic biomarker and therapeutic target in osteosarcoma. Ther Adv Musculoskelet Dis. 2021;13. doi: 10.1177/1759720X21995069
Sage Publishing was contacted by the authors, requesting a replacement of Figure 5C’s U-20S 0 µM treatment control panel. The authors explained that they accidentally inserted the KHOS 0 µM treatment control panel twice in the creation of this figure.
During an internal review of the remaining figures, further concerns were raised, specifically:
In Figure 2A, lane 2 of the Tubulin panel appears different compared to the background of the other Western blot lanes.
In Figure 4C, lanes 3,4, and 5 of the CDk7 panel, appear to have different backgrounds compared to the other Western blot lanes.
In Figure 4C, lanes 4 and 5 of the RNAPII ser5 panel, appear to have an image overlaid.
In Figure 4D, lane 1 of the CDK7 panel appears to have a background that differs compared to the other Western blot lanes.
In Figure 5D, lane 5 of the CDK7 panel appears to have an adjusted background compared to the other Western blot lanes.
In Figure 5D, there is an apparent splice line between lanes 4 and 5 of the Mcl-1 panel
In Figure 5F, lanes 2 and 3 of the RNAPII panel appear to have a different background compared to the other Western blot lanes.
In Figure 5F, there appears to be an apparent splice line between lanes 1 and 2 of the Mcl-1 panel.
The authors provided the images underlying these figures for assessment, but Sage Publishing is unable to validate the integrity of these images as they do not meet our criteria of raw, unedited images of the experiments conducted.
This article has been retracted due to uncertainty around the integrity of the original images that call into question the validity of the findings.
The authors did not respond for comment when notified of this retraction.